Gastroesophageal reflux disease symptom severity, proton pump inhibitor use, and esophageal carcinogenesis

Archives of Surgery

Volumn 146, Issue 7, 2011, Pages 851-858

  Nason, Katie S ^a   Wichienkuer, Promporn Paula ^b   Awais, Omar ^a   Schuchert, Matthew J ^a   Luketich, James D ^a   O'Rourke, Robert W ^c   Hunter, John G ^c   Morris, Cynthia D ^b   Jobe, Blair A ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYMPTOM;

BARRETT ESOPHAGUS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OREGON; PREVALENCE; PROTON PUMP INHIBITORS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79960418060     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.2011.174     Document Type: Article

References (51)

1. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825-831. (Pubitemid 29142625)
2. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998;90(2):150-155. (Pubitemid 28114417)
3. Lieberman DA, Oehlke M, Helfand M; Gastroenterology Outcomes Research Group in Endoscopy. Risk factors for Barrett's esophagus in community-based practice: GORGE consortium. Am J Gastroenterol. 1997;92(8):1293-1297.
4. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92(2):212-215. (Pubitemid 27076463)
5. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1995;4(2):85-92.
6. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005;97(11):1471- 1478. (Pubitemid 41642525)
7. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122(1):26-33. (Pubitemid 34049191)
8. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastroenterol. 1997;92(1):27-31. (Pubitemid 27027023)
9. Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97(8):1888-1895.
10. Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 1998;93(7):1028-1032.
11. Wang KK, Sampliner RE; Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103(3):788-797.
12. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007;20(2):130-134. (Pubitemid 46562851)
13. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274-277. (Pubitemid 36626833)
14. Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006;101(12):2693-2703. (Pubitemid 44902638)
15. Velanovich V. Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL) quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg. 1998;2(2):141-145. (Pubitemid 128432024)
16. Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the Health-Related Quality of Life score and physiologic parameters. Am Surg. 1998;64(7):649-653. (Pubitemid 28294691)
17. Wallner B, Sylvan A, Janunger K-G. Endoscopic assessment of the "Z-line" (squa-mocolumnar junction) appearance: reproducibility of the ZAP classification among endoscopists. Gastrointest Endosc. 2002;55(1):65-69. (Pubitemid 41122926)
18. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol. 2000;95(11):3089-3096.
19. Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol. 2000;95(5):1152-1157. (Pubitemid 30263505)
20. Lewin KJ, Appleman HD. Tumors of the esophagus and stomach. In: Atlas of Tumor Pathology. Vol 18. Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology; 1996.
21. Nasseri-Moghaddam S, Razjouyan H, Nouraei M, et al. Inter- and intra-observer variability of the Los Angeles classification: a reassessment [published correction appears in Arch Iran Med. 2007;10(3):429]. Arch Iran Med. 2007;10(1):48-53.
22. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172-180. (Pubitemid 29333764)
23. Hosmer DW, Lemeshow S. Applied Logistic Regression. Hoboken, NJ: John Wiley & Sons, Inc; 2000.
24. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in older people: a study of 840 consecutive patients. J Am Geriatr Soc. 2006;54(10):1537-1542. (Pubitemid 44564148)
25. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049-2053. (Pubitemid 28525384)
26. Brown LM, Devesa SS, Chow W-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184-1187.
27. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
28. Korkmaz M, Tarhan E, Unal H, Selcuk H, Yilmaz U, Ozluoglu L. Esophageal mucosal sensitivity: possible links with clinical presentations in patients with erosive esophagitis and laryngopharyngeal reflux. Dig Dis Sci. 2007;52(2):451-456. (Pubitemid 46202820)
29. Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus. Dig Dis Sci. 1997;42(9):1853-1858. (Pubitemid 27433532)
30. Grade A, Pulliam G, Johnson C, Garewal H, Sampliner RE, Fass R. Reduced chemo-receptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium. Am J Gastroenterol. 1997;92(11):2040-2043. (Pubitemid 27476246)
31. Niemantsverdriet EC, Timmer R, Breumelhof R, Smout AJ. The roles of excessive gastro-oesophageal reflux, disordered oesophageal motility and decreased mucosal sensitivity in the pathogenesis of Barrett's oesophagus. Eur J Gastroenterol Hepatol. 1997;9(5):515-519. (Pubitemid 27214459)
32. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120(7):1599-1606. (Pubitemid 32523479)
33. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther. 2004;20(6):637-643. (Pubitemid 39279052)
34. Vallböhmer D, DeMeester SR, Peters JH, et al. Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis Esophagus. 2006;19(4):260-266. (Pubitemid 44027088)
35. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;117(2):327-335. (Pubitemid 29352940)
36. Burnat G, Rau T, Elshimi E, Hahn EG, Konturek PC. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol. 2007;42(12):1460-1465. (Pubitemid 350125549)
37. Kazumori H, Ishihara S, Rumi MAK, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut. 2006;55(1):16-25. (Pubitemid 41820630)
38. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96(7):2005-2012. (Pubitemid 32660890)
39. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58(5):661-670. (Pubitemid 37370477)
40. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33(4):306-309. (Pubitemid 32880970)
41. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130(11):883-890. (Pubitemid 29239582)
42. Salem SB, Kushner Y, Marcus V, Mayrand S, Fallone CA, Barkun AN. The potential impact of contemporary developments in the management of patients with gastroesophageal reflux disease undergoing an initial gastroscopy. Can J Gastroenterol. 2009;23(2):99-104.
43. Nandurkar S, Locke GR III, Murray JA, et al. Rates of endoscopy and endoscopic findings among people with frequent symptoms of gastroesophageal reflux in the community. Am J Gastroenterol. 2005;100(7):1459-1465. (Pubitemid 41032348)
44. Dickman R, Mattek N, Holub J, Peters D, Fass R. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol. 2007;102(6):1173-1179. (Pubitemid 46802000)
45. Fan X, Snyder N. Prevalence of Barrett's esophagus in patients with or without GERD symptoms: role of race, age, and gender. Dig Dis Sci. 2009;54(3):572-577.
46. Poelmans J, Feenstra L, Demedts I, Rutgeerts P, Tack J. The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol. 2004;99(8):1419- 1426. (Pubitemid 39180084)
47. Toruner M, Soykan I, Ensari A, Kuzu I, Yurdaydin C, Özden A. Barrett's esophagus: prevalence and its relationship with dyspeptic symptoms. J Gastroenterol Hepatol. 2004;19(5):535-540. (Pubitemid 38669901)
48. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev. 2009;18(2):526-533.
49. García Rodríguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55(11):1538-1544. (Pubitemid 44629198)
50. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci. 2003;48(12):2237-2241. (Pubitemid 38021725)
51. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2004;2(8):665-668. (Pubitemid 39013425)